Evidence map›Paper›PMID 40208412›Full record

ReviewInfectious diseases and therapy2025

Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control-A Narrative Review.

Andreea M Sandu, Mariana C Chifiriuc, Corneliu O Vrancianu, Roxana-E Cristian, Cristina F Alistar, Marian Constantin, Mihaela Paun, Alexandru Alistar, Loredana G Popa, Mircea I Popa and 6 more

Abstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Combined Fibrinogen and Urinary α1-Microglobulin as Predictors of Respiratory Tract Infection in Children with Nephrotic Syndrome.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  3. Beyond the Reported Numbers:Antibiotics (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Methicillin-ResistantMicroorganisms · 2026
    Review
  13. Article
  14. Genetic Determinants Linked to MDR/XDR inPathogens (Basel, Switzerland) · 2026
    Article
  15. Article
  16. Article
  17. Antimicrobial Stewardship in oral and maxillofacial surgery: melting the iceberg.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andreea M SanduDoctoral School, Carol Davila University of Medicine and Pharmacy, Eroii Sanitari 8, District 5, 050474, Bucharest, Romania.
Mariana C ChifiriucThe Research Institute of the University of Bucharest, ICUB, Șoseaua Panduri 90, District 5, 050663, Bucharest, Romania.
Corneliu O VrancianuDoctoral School, Carol Davila University of Medicine and Pharmacy, Eroii Sanitari 8, District 5, 050474, Bucharest, Romania. ovidiu.vrancianu@incdsb.ro.ORCID http://orcid.org/0000-0002-2409-0966
Roxana-E CristianThe Research Institute of the University of Bucharest, ICUB, Șoseaua Panduri 90, District 5, 050663, Bucharest, Romania.
Cristina F AlistarThe Research Institute of the University of Bucharest, ICUB, Șoseaua Panduri 90, District 5, 050663, Bucharest, Romania.
Marian ConstantinThe Research Institute of the University of Bucharest, ICUB, Șoseaua Panduri 90, District 5, 050663, Bucharest, Romania.
Mihaela PaunNational Institute of Research and Development for Biological Sciences, 296 Splaiul Independentei, District 6, 060031, Bucharest, Romania.
Alexandru AlistarThe Research Institute of the University of Bucharest, ICUB, Șoseaua Panduri 90, District 5, 050663, Bucharest, Romania.
Loredana G PopaFaculty of Medicine, Microbiology Discipline II, Carol Davila University of Medicine and Pharmacy, 020021, Bucharest, Romania.
Mircea I PopaFaculty of Medicine, Microbiology Discipline II, Carol Davila University of Medicine and Pharmacy, 020021, Bucharest, Romania.
Ana C TantuUniversity of Medicine and Pharmacy of Craiova, Petru Rareș 2, 200349, Craiova, Romania.
Manuela E SidoroffNational Institute of Research and Development for Biological Sciences, 296 Splaiul Independentei, District 6, 060031, Bucharest, Romania.
Mara M MihaiFaculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021, Bucharest, Romania.
Andreea MarcuFaculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021, Bucharest, Romania.
George PopescuDepartment of Neurosurgery 4, Bagdasar-Arseni Emergency Clinical Hospital, Şoseaua Berceni 12, 041915, Bucharest, Romania.
Monica M TantuDepartment of Medical Assistance and Physical Therapy, Pitesti University Center, Târgu din Vale 1, 110040, Piteşti, Romania.

Funding

Institute of Biology Bucharest of the Romanian Academy Project No. RO1567-IBB05/2023Ministry of Research, Innovation and Digitalization through the National Recovery and Resilience Plan (PNRR) of Romania Component C9/Investment no. 8 (I8) - contract CF 68Ministry of Research, Innovation and Digitalization through the National Recovery and Resilience Plan (PNRR) of Romania Pillar IIIROGEN Dezvoltarea cercetării genomice în România - ROGEN" (Development of genomic research in Romania -ROGEN).The core program within the National Research Development and Innovation Plan, 2022-2027', carried out with the support of the Ministry of Research, Innovation and Digitalization (MCID), Contract no. 7N from 3 January 2023The core program within the National Research Development and Innovation Plan, 2022-2027', carried out with the support of the Ministry of Research, Innovation and Digitalization (MCID), project no. 23020101University of Bucharest CNFIS-FDI-2024-F-0484 INOVEX
6 · The paper itself

Abstract

Healthcare-associated infections (HAIs), previously known as nosocomial infections, represent a significant threat to healthcare systems worldwide, prolonging patient hospital stays and the duration of antimicrobial therapy. One of the most serious consequences of HAIs is the increase in the rate of antibiotic resistance (AR) generated by the prolonged, frequent, and sometimes incorrect use of antibiotics, which leads to the selection of resistant bacteria, making treatment difficult and expensive, with direct consequences for the safety of patients and healthcare personnel. Therefore, timely and accurate diagnosis of HAIs is mandatory to develop appropriate infection prevention and control practices (IPC) and new therapeutic strategies. This review aimed to present the prevalence, risk factors, current diagnosis, including artificial intelligence (AI) and machine learning approaches, future perspectives in combating HAIs causative bacteria (phage therapy, microbiome-based interventions, and vaccination), and HAIs surveillance strategies. Also, we discussed the latest findings regarding the relationships of AR with climate change and environmental pollution in the context of the One Health approach. Phage therapy is an emerging option that can offer an alternative to ineffective antibiotic treatments for antibiotic-resistant bacteria causing HAIs. Clinical trials dealing with vaccine development for resistant bacteria have yielded conflicting results. Two promising strategies, fecal microbiota transplantation and probiotic therapy, proved highly effective against recurrent Clostridium difficile infections and have been shown to reduce HAI incidence in hospitalized patients undergoing antibiotic therapy. Artificial intelligence and machine learning systems offer promising predictive capabilities in processing large volumes of clinical, microbiological, and patient data but require robust data integration. Our paper argues that HAIs are still a global challenge, requiring stringent IPC policies, computer vision, and AI-powered tools. Despite promising avenues like integrated One Health approaches, optimized phage therapy, microbiome-based interventions, and targeted vaccine development, several knowledge gaps in clinical efficacy, standardization, and pathogen complexity remain to be answered.

Indexed as

DysbiosisHospital-acquired infectionsMicrobiomeMultidrug resistantOne-HealthPhage therapyVaccines

Identifiers

PMID40208412
PMCPMC12084486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.